These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 12094865)
1. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Esters N; Vermeire S; Joossens S; Noman M; Louis E; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; Poulain D; Bossuyt X; Rutgeerts P; Am J Gastroenterol; 2002 Jun; 97(6):1458-62. PubMed ID: 12094865 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542 [TBL] [Abstract][Full Text] [Related]
3. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1. Yacyshyn BR; Schievella A; Sewell KL; Tami JA Clin Exp Immunol; 2005 Jul; 141(1):141-7. PubMed ID: 15958080 [TBL] [Abstract][Full Text] [Related]
4. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Koutroubakis IE; Petinaki E; Mouzas IA; Vlachonikolis IG; Anagnostopoulou E; Castanas E; Maniatis AN; Kouroumalis EA Am J Gastroenterol; 2001 Feb; 96(2):449-54. PubMed ID: 11232689 [TBL] [Abstract][Full Text] [Related]
5. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007 [TBL] [Abstract][Full Text] [Related]
6. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Amre DK; Lu SE; Costea F; Seidman EG Am J Gastroenterol; 2006 Mar; 101(3):645-52. PubMed ID: 16464223 [TBL] [Abstract][Full Text] [Related]
7. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P; Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256 [TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301 [TBL] [Abstract][Full Text] [Related]
9. Infliximab use in luminal Crohn's disease. Richter JA; Bickston SJ Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813 [TBL] [Abstract][Full Text] [Related]
10. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China. Zhou F; Xia B; Wang F; Shrestha UK; Chen M; Wang H; Shi X; Chen Z; Li J Clin Chim Acta; 2010 Oct; 411(19-20):1461-5. PubMed ID: 20570669 [TBL] [Abstract][Full Text] [Related]
11. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096 [TBL] [Abstract][Full Text] [Related]
12. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255 [TBL] [Abstract][Full Text] [Related]
13. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases]. Mokrowiecka A; Gasiorowska A; Małecka-Panas E Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341 [TBL] [Abstract][Full Text] [Related]
14. Clinical utility of serological markers in inflammatory bowel disease. Mokrowiecka A; Daniel P; Słomka M; Majak P; Malecka-Panas E Hepatogastroenterology; 2009; 56(89):162-6. PubMed ID: 19453050 [TBL] [Abstract][Full Text] [Related]
15. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Teml A; Kratzer V; Schneider B; Lochs H; Norman GL; Gangl A; Vogelsang H; Reinisch W Am J Gastroenterol; 2003 Oct; 98(10):2226-31. PubMed ID: 14572572 [TBL] [Abstract][Full Text] [Related]
16. The clinical significance of antimicrobial serologic responses within an Irish Crohn's disease population. O'Donnell S; O'Sullivan M; O'Morain CA; Ryan BM Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1464-9. PubMed ID: 24047859 [TBL] [Abstract][Full Text] [Related]
17. pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease. Mokrowiecka A; Gasiorowska A; Malecka-Panas E Hepatogastroenterology; 2007; 54(77):1443-8. PubMed ID: 17708273 [TBL] [Abstract][Full Text] [Related]
18. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Gao Q; Hogezand RA; Lamers CB; Verspaget HW Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330 [TBL] [Abstract][Full Text] [Related]
19. Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction. Vandewalle-El Khoury P; Colombel JF; Joossens S; Standaert-Vitse A; Collot M; Halfvarson J; Ayadi A; Landers CJ; Vermeire S; Rutgeerts P; Targan SR; Chamaillard M; Mallet JM; Sendid B; Poulain D Am J Gastroenterol; 2008 Apr; 103(4):949-57. PubMed ID: 18047546 [TBL] [Abstract][Full Text] [Related]
20. [Interest of serologic markers in inflammatory bowel disease. About 105 cases]. Fekih M; Ben Hlima S; Zitouni M; Matri S; Boubaker J; Makni S; Azza F Tunis Med; 2007 Oct; 85(10):821-8. PubMed ID: 18236802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]